CD30 has long been recognized as a unique antigen on lymphomas of T or B origin of immature to the fully differentiated state. CD30 moreover has been found to be associated with disease progression in anaplastic large cell lymphoma. CD30 is expressed as a disease marker in allergic conditions and CD30 expression is associated with progression of HIV disease, with Epstein-Bar virus infection and transformation and with HTLV associated lymphomas. Finally, CD30 over-expression is found in Omenn's syndrome, a severe combined immunodeficiency of unknown etiology, characterized by high Il-5 levels, eosinophilia and IgE production. CD30 signaling functions via TRAF proteins have recently been elucidated. Similar to other members of the TNF-R family of receptors, CD30 signals have a dual role for activation, proliferation and anti-apoptosis; or for apoptosis. CD30 expression itself is favored by a TH2 environment and suppressed by Ifn-gamma. It is postulated and will be tested in this application that CD30 expressed on lymphomas provides a selective advantage to lymphomas or other CD30 positive cells through its co- stimulatory activity, by promoting proliferation and increasing resistance to apoptosis. This hypothesis will be examined 1. by analyzing pathways regulating TRAF2 activity which is primarily responsible for anti apoptotic signals through Jun-N-terminal kinase (JNK) and NFkappaB activation; 2. by CD30-L gene ablation to eliminate CD30-L triggered CD30 signals and signaling by CD30 induction on ongoing immune responses to tumors in vivo and in vitro.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG2-IMS (01))
Program Officer
Finerty, John F
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Miami School of Medicine
Schools of Medicine
United States
Zip Code
Muta, Hiromi; Podack, Eckhard R (2013) CD30: from basic research to cancer therapy. Immunol Res 57:151-8
Zimmerman, Zachary; Shatry, Alwi; Deyev, Vadim et al. (2005) Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis fa Biol Blood Marrow Transplant 11:576-86
Strbo, Natasa; Oizumi, Satoshi; Sotosek-Tokmadzic, Vlatka et al. (2003) Perforin is required for innate and adaptive immunity induced by heat shock protein gp96. Immunity 18:381-90
Merger, M; Viney, J L; Borojevic, R et al. (2002) Defining the roles of perforin, Fas/FasL, and tumour necrosis factor alpha in T cell induced mucosal damage in the mouse intestine. Gut 51:155-63
Podack, Eckhard R; Strbo, Natasa; Sotosec, Vlatka et al. (2002) CD30-governor of memory T cells? Ann N Y Acad Sci 975:101-13
Nam, Sang Yun; Cho, Kyong Shin; Heo, Young Moon et al. (2002) Regulation of lymphocyte clustering by CD30-mediated ICAM-1 up-regulation. Cell Immunol 219:38-47
Strbo, Natasa; Yamazaki, Koichi; Lee, Kelvin et al. (2002) Heat shock fusion protein gp96-Ig mediates strong CD8 CTL expansion in vivo. Am J Reprod Immunol 48:220-5
Toomey, N L; Deyev, V V; Wood, C et al. (2001) Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma. Oncogene 20:7029-40
Jiang, Z; Podack, E; Levy, R B (2001) Major histocompatibility complex-mismatched allogeneic bone marrow transplantation using perforin and/or Fas ligand double-defective CD4(+) donor T cells: involvement of cytotoxic function by donor lymphocytes prior to graft-versus-host disease pathogenes Blood 98:390-7
Muta, H; Boise, L H; Fang, L et al. (2000) CD30 signals integrate expression of cytotoxic effector molecules, lymphocyte trafficking signals, and signals for proliferation and apoptosis. J Immunol 165:5105-11

Showing the most recent 10 out of 12 publications